BR9506507A - Galenic form of 5-nitro-imadazole derivatives pharmaceutical compositions gastro-protected microgranules of 5-nitro-imidazole derivatives and combination product - Google Patents

Galenic form of 5-nitro-imadazole derivatives pharmaceutical compositions gastro-protected microgranules of 5-nitro-imidazole derivatives and combination product

Info

Publication number
BR9506507A
BR9506507A BR9506507A BR9506507A BR9506507A BR 9506507 A BR9506507 A BR 9506507A BR 9506507 A BR9506507 A BR 9506507A BR 9506507 A BR9506507 A BR 9506507A BR 9506507 A BR9506507 A BR 9506507A
Authority
BR
Brazil
Prior art keywords
nitro
derivatives
microgranules
gastro
pharmaceutical compositions
Prior art date
Application number
BR9506507A
Other languages
Portuguese (pt)
Inventor
Gerard Leduc
Patrice Debregeas
Original Assignee
Ethypharm Lab Prod Ethiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9400394A external-priority patent/FR2715067B1/en
Application filed by Ethypharm Lab Prod Ethiques filed Critical Ethypharm Lab Prod Ethiques
Publication of BR9506507A publication Critical patent/BR9506507A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Medicinal form contains a combination of microgranules of derivatives 5-nitroimidasole, consisting, on the one hand, of gastro-resistant microgranules and, on the other hand, of microgranules with a prolonged release of a medicinal agent. Gastroresistant microgranules are intended to guarantee the efficiency of the medicinal form of the present invention, primarily, in the upper part of gastrointestinal tract, while the microgranules with a prolonged medicinal agent release are operate mainly in the lower part of gastrointestinal tract.
BR9506507A 1994-01-14 1995-01-12 Galenic form of 5-nitro-imadazole derivatives pharmaceutical compositions gastro-protected microgranules of 5-nitro-imidazole derivatives and combination product BR9506507A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9400394A FR2715067B1 (en) 1994-01-14 1994-01-14 New dosage form of 5-nitro-imidazole derivatives effective for the treatment of parasitic infections and infections of the entire gastrointestinal tract.
PCT/FR1995/000039 WO1995019168A1 (en) 1994-01-14 1995-01-12 Microgranules of 5-nitro imidazole derivatives

Publications (1)

Publication Number Publication Date
BR9506507A true BR9506507A (en) 1997-09-09

Family

ID=9459066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506507A BR9506507A (en) 1994-01-14 1995-01-12 Galenic form of 5-nitro-imadazole derivatives pharmaceutical compositions gastro-protected microgranules of 5-nitro-imidazole derivatives and combination product

Country Status (19)

Country Link
JP (1) JPH09507499A (en)
KR (1) KR100320140B1 (en)
CN (1) CN1088357C (en)
AT (1) ATE187068T1 (en)
AU (1) AU705570B2 (en)
BR (1) BR9506507A (en)
CZ (1) CZ286080B6 (en)
DE (1) DE69513632T2 (en)
DK (1) DK0739201T3 (en)
ES (1) ES2139883T3 (en)
MA (1) MA23429A1 (en)
MX (1) MX9602772A (en)
NZ (1) NZ279238A (en)
OA (1) OA10583A (en)
PL (1) PL178424B1 (en)
PT (1) PT739201E (en)
RU (1) RU2152212C1 (en)
SK (1) SK282066B6 (en)
UA (1) UA28031C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4331930B2 (en) * 2001-10-17 2009-09-16 武田薬品工業株式会社 High content granules of acid labile drugs
KR20170052626A (en) 2014-09-05 2017-05-12 심바이오믹스 세러퓨틱스 엘엘씨 Secnidazole for use in the treatment of bacterial vaginosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
DE3822095A1 (en) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab NEW MEDICAMENT FORMULATION AND METHOD FOR THE PRODUCTION THEREOF
AU7909691A (en) * 1990-05-14 1991-12-10 Gary R. Jernberg Surgical implant and method incorporating chemotherapeutic agents

Also Published As

Publication number Publication date
DE69513632D1 (en) 2000-01-05
PL315530A1 (en) 1996-11-12
AU705570B2 (en) 1999-05-27
MX9602772A (en) 1997-05-31
CZ286080B6 (en) 2000-01-12
SK91496A3 (en) 1996-12-04
CN1088357C (en) 2002-07-31
CN1138826A (en) 1996-12-25
NZ279238A (en) 1998-03-25
AU1580395A (en) 1995-08-01
PL178424B1 (en) 2000-04-28
UA28031C2 (en) 2000-10-16
DK0739201T3 (en) 2000-05-01
MA23429A1 (en) 1995-10-01
DE69513632T2 (en) 2000-04-06
ES2139883T3 (en) 2000-02-16
KR100320140B1 (en) 2002-07-02
SK282066B6 (en) 2001-10-08
ATE187068T1 (en) 1999-12-15
JPH09507499A (en) 1997-07-29
CZ205596A3 (en) 1996-10-16
OA10583A (en) 2002-07-10
RU2152212C1 (en) 2000-07-10
PT739201E (en) 2000-05-31

Similar Documents

Publication Publication Date Title
FR15C0024I2 (en) 6-SUBSTITUTED INDOLINONES, THEIR PREPARATION AND THEIR USE AS MEDICINES
BR0010750A (en) Long-acting insulinotropic peptides
DE60143393D1 (en) MODIFIED FORMS PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF
TR200002299T2 (en) Epothilon compositions.
EE200100618A (en) A dietary or pharmaceutical composition for use in the prevention or treatment of hyperoxaluria
DE69604653T2 (en) TAXOL DERIVATIVES, THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BR1100776A (en) Compressed pharmaceutical dosage form and compressed pharmaceutical burden.
HK1034455A1 (en) Oral pharmaceutical extended release dosage form.
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
NZ505073A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant, useful for treating allergic, inflammatory and intestinal diseases
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
ITMI20022292A1 (en) 9A-AZALIDS WITH ANTI-INFLAMMATORY ACTIVITY.
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
DK1225902T3 (en) Ciclesonide-containing pharmaceutical composition for administration to the mucosa
DE69706146D1 (en) TAXOIDS, THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PA8449301A1 (en) PHARMACEUTICAL COMPOSITIONS
AU1751997A (en) Targeted delivery of drugs to the lower gastrointestinal tract
BR9506507A (en) Galenic form of 5-nitro-imadazole derivatives pharmaceutical compositions gastro-protected microgranules of 5-nitro-imidazole derivatives and combination product
WO2000058466A3 (en) Protease resistant flint analogs
TR200102930T2 (en) The use of osanetate in the production of drugs useful in the treatment of mental disorders
WO2001022917A8 (en) Effervescent compositions comprising nimesulide
HUP0200529A2 (en) Optically pure camptothecin analogues, pharmaceutical compositions containing them and their use
HUP0202594A3 (en) Streptogramin derivatives, production thereof and pharmaceutical compositions containing the same
WO2001030372A3 (en) Pharmaceutical agent preparations

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 11A, 12A, 13A, 14A, 15A, 16A, 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.